Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease

被引:5
|
作者
Alexopoulos, Panagiotis [1 ,2 ]
Roesler, Jennifer [2 ]
Werle, Lukas [2 ,3 ]
Thierjung, Nathalie [2 ]
Lentzari, Iliana [1 ]
Ortner, Marion [2 ]
Grimmer, Timo [2 ]
Laskaris, Nikolaos [4 ]
Politis, Antonios [5 ,6 ]
Gourzis, Philippos [1 ]
Kurz, Alexander [2 ]
Perneczky, Robert [7 ,8 ,9 ,10 ]
机构
[1] Univ Patras, Dept Psychiat, Rion 26500, Greece
[2] Tech Univ Munich, Dept Psychiat & Psychotherapy, Ismaninger Str 22, D-81675 Munich, Germany
[3] Max Planck Inst Psychiat, Munich, Germany
[4] Aristotle Univ Thessaloniki, Dept Informat, Thessaloniki 54124, Greece
[5] Univ Athens, Eginit Hosp, Dept Psychiat 1, Vassilissis Sofias Ave 72-74, Athens 11528, Greece
[6] Johns Hopkins Med Sch, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Baltimore, MD USA
[7] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany
[8] Imperial Coll Sci Technol & Med, Sch Publ Hlth, Neuroepidemiol & Ageing Res Unit, Fac Med, London, England
[9] West London Mental Hlth NHS Trust, London, England
[10] German Ctr Neurodegenerat Dis DZNE Munich, Munich, Germany
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
beta-Amyloid; 1-42; Total tau; Phosphorylated tau 181; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; CSF BIOMARKERS; AMYLOID-BETA; DIAGNOSTIC EVALUATION; TAU PATHOLOGY; RECOMMENDATIONS; DECLINE; MARKERS;
D O I
10.1007/s00702-017-1810-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The cerebrospinal fluid (CSF) levels of beta-amyloid 42, total tau, and phosphorylated tau 181 are supposed to be all continuously abnormal in dementia due to Alzheimer's disease (AD), being the most advanced disease stage. The aim of the present study, which included a monocentric and a multicentric sample (N = 119 and 178, respectively), was to investigate the degree of CSF biomarker agreement and interrelation in AD dementia. Based on previously published cut-off values, biomarker values were categorized as positive or negative for AD (dichotomization strategy) and as either positive, negative, or borderline (trichotomization strategy). The statistical analyses relied on distance correlation analysis and kappa (k) statistics. Poor agreement (k < 0.4) and low interrelations between the studied biomarkers were detected in all cases with the exception of the interrelation between the markers total tau and phosphorylated tau 181, especially in the monocentric sample. Interestingly, lower interrelation and agreement degrees were observed in carriers of the Apolipoprotein E epsilon 4 allele compared to non-carriers. The clinical phenotype currently referred to as "AD dementia" is characterized by an inhomogeneous CSF biomarker profile, possibly mirroring the complex genesis of AD-typical dementia symptoms and pointing to the necessity of shedding more light on the hypothesis of biomarker stability over time in symptomatic AD.
引用
收藏
页码:193 / 201
页数:9
相关论文
共 50 条
  • [31] Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis
    Bjerke, Maria
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (03) : 1199 - 1209
  • [32] Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature
    Milos, Tina
    Vuic, Barbara
    Balic, Nikola
    Farkas, Vladimir
    Erjavec, Gordana Nedic
    Strac, Dubravka Svob
    Perkovic, Matea Nikolac
    Pivac, Nela
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (11) : 1063 - 1079
  • [33] Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease
    Gomar, Jesus J.
    Conejero-Goldberg, Concepcion
    Davies, Peter
    Goldberg, Terry E.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 51 (04) : 1085 - 1096
  • [34] YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
    Craig-Schapiro, Rebecca
    Perrin, Richard J.
    Roe, Catherine M.
    Xiong, Chengjie
    Carter, Deborah
    Cairns, Nigel J.
    Mintun, Mark A.
    Peskind, Elaine R.
    Li, Ge
    Galasko, Douglas R.
    Clark, Christopher M.
    Quinn, Joseph F.
    D'Angelo, Gina
    Malone, James P.
    Townsend, R. Reid
    Morris, John C.
    Fagan, Anne M.
    Holtzman, David M.
    BIOLOGICAL PSYCHIATRY, 2010, 68 (10) : 903 - 912
  • [35] Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease
    Gaetani, Lorenzo
    Chiasserini, Davide
    Paoletti, Federico Paolini
    Bellomo, Giovanni
    Parnetti, Lucilla
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2023, 23 (12) : 1195 - 1207
  • [36] Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease
    Counts, Scott E.
    He, Bin
    Prout, John G.
    Michalski, Bernadeta
    Farotti, Lucia
    Fahnestock, Margaret
    Mufson, Elliott J.
    CURRENT ALZHEIMER RESEARCH, 2016, 13 (07) : 800 - 808
  • [37] Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Zetterberg, H
    Wahlund, LO
    Blennow, K
    NEUROSCIENCE LETTERS, 2003, 352 (01) : 67 - 69
  • [38] The Past and the Future of Alzheimer's Disease Fluid Biomarkers
    Blennow, Kaj
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (03) : 1125 - 1140
  • [39] Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel
    Somers, Charisse
    Goossens, Joery
    Engelborghs, Sebastiaan
    Bjerke, Maria
    BIOMARKERS IN MEDICINE, 2017, 11 (02) : 169 - 178
  • [40] Oscillatory connectivity as a diagnostic marker of dementia due to Alzheimer's disease
    Musaeus, Christian Sandoe
    Engedal, Knut
    Hogh, Peter
    Jelic, Vesna
    Morup, Morten
    Naik, Mala
    Oeksengaard, Anne-Rita
    Snaedal, Jon
    Wahlund, Lars-Olof
    Waldemar, Gunhild
    Andersen, Birgitte Bo
    CLINICAL NEUROPHYSIOLOGY, 2019, 130 (10) : 1889 - 1899